Pharmaceutical Technology5d
YTS-109 by Bristar Immunotech Biotechnology for Polymyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.
Pharmaceutical Technology5d
YTS-109 by Bristar Immunotech Biotechnology for Dermatomyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Dermatomyositis.
hss.edu6d
Catastrophic Antiphospholipid Syndrome
1. What is antiphospholipid syndrome (APS)? Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the patient’s immune system makes antibodies (antiphospholipid antibodies [aPL]) ...
C&EN5d
A Lipidomic Study to Identify the Serum Lipid Markers for Obstetric Antiphospholipid Syndrome
Department of Obstetrics and Gynecology, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing 210004, China Department of Obstetrics, Women and ...